market access

Teva’s Cinqaero to challenge Nucala after clearing NICE

July 20, 2017

Discount swings NICE decision, drug will compete with GSK rival

Teva’s Cinqaero to challenge Nucala after clearing NICE

https://pharmaphorum.com/news/nice-recommends-teva-asthma-drug/

Alexion price cut opens up Strensiq to more patients

July 5, 2017

Managed access scheme will control costs to NHS.

Alexion price cut opens up Strensiq to more patients

https://pharmaphorum.com/news/alexions-strensiq-available-patients-nice-rethink/

Accelerating clinical research in Brazil

July 3, 2017

Developments that promise to improve clinical research in Brazil.

Accelerating clinical research in Brazil

https://pharmaphorum.com/views-and-analysis/accelerating-clinical-research-brazil/

Sobi drug gains NICE approval after 4 year wait

June 30, 2017

Sobi’s Xiapex recommended after reassessment.

Sobi drug gains NICE approval after 4 year wait

https://pharmaphorum.com/news/nice-finally-recommends-hand-contracture-drug/

NICE green light a win for Lilly in RA market

June 30, 2017

RA drug backed after manufacturer offered discount.

NICE green light a win for Lilly in RA market

https://pharmaphorum.com/news/lillys-olumiant-recommended-nice/

Kisqali set for approval – but likely to hit same NICE obstacles as rival

June 28, 2017

Concerns that NICE will reject Kisqali like it did Ibrance.

Kisqali set for approval – but likely to hit same NICE obstacles as rival

https://pharmaphorum.com/news/will-patients-access-novartis-breast-cancer-drug-england/

Gottlieb outlines FDA plan to keep generics cheap

June 22, 2017

Reports also suggest Trump’s pricing plans may be pro-industry.

Gottlieb outlines FDA plan to keep generics cheap

https://pharmaphorum.com/news/scott-gottlieb-generics-cheap/

Immuno-oncology drugs: key to the Cancer Moonshot?

June 21, 2017

Assessing the global challenges inhibiting immuno-oncology market access.

Immuno-oncology drugs: key to the Cancer Moonshot?

https://pharmaphorum.com/views-and-analysis/immuno-oncology-drugs-key-cancer-moonshot/

Kadcyla finally gets OK after price cut and NICE concessions

June 16, 2017

Roche’s breast cancer drug Kadcyla is set for regular NHS funding in England after the company finally agreed

Kadcyla finally gets OK after price cut and NICE concessions

https://pharmaphorum.com/news/kadcyla-set-regular-nhs-funding-nice-backing/

1 2 3 4 5 >»

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com

Trending

market access

Teva’s Cinqaero to challenge Nucala after clearing NICE

Alexion price cut opens up Strensiq to more patients

Accelerating clinical research in Brazil

Sobi drug gains NICE approval after 4 year wait

NICE green light a win for Lilly in RA market

Kisqali set for approval – but likely to hit same NICE obstacles as rival

Gottlieb outlines FDA plan to keep generics cheap

Immuno-oncology drugs: key to the Cancer Moonshot?

Kadcyla finally gets OK after price cut and NICE concessions

Inhalation and Respiratory Drug Products Summit

THET Annual Conference 2017

Clinical Trial Supply East Coast 2017

Livongo’s diabetes solution impresses in latest study

Vifor’s hyperkalaemia drug Veltassa approved in Europe

New 3-year data supports Kite ‘cure’ hopes for CAR-T

Daiichi Sankyo anticoagulant gains EU label boost

Teva’s Cinqaero to challenge Nucala after clearing NICE

The most notable digital health trends of 2017 so far

Europe has untapped medical innovation – but needs high speed connections to make it work

Healthcare’s hype cycle: which technologies will stay the course?

Looking back, looking forward – Janssen’s 60 years on the psychiatry horizon

What HCPs say about Roche’s breast cancer drug

Search

Advanced Search

Trending

market access